Gastroenterology Associates, PA

Greenville, South Carolina 29615

1 studies enrolling now · 19 studies all time

What they study most

Celiac Disease, Colitis, Ulcerative, Colo-rectal Cancer, Colorectal Cancer, Crohn Disease, Crohn's Disease, Diabetes Mellitus, Gastroesophageal Reflux Disease (GERD), Gastroparesis, Ulcerative Colitis

Studies at this site

• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
• A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
• ABTECT - Maintenance — Running, not enrolling
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics — Running, not enrolling
• A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis — Completed
• ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 — Completed
• A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet — Completed
• Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year — Completed
• Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis — Completed
• A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03 — Stopped early
• Diabetic Gastroparesis Study 05 — Stopped early
• A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04 — Stopped early
• Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs) — Completed
• A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01 — Stopped early
• An Evaluation of a Multi-target Stool DNA (Mt-sDNA) Test, Cologuard, for CRC Screening in Individuals Aged 45-49 and at Average Risk for Development of Colorectal Cancer: Act Now — Completed
• Blood Collection Sub-Study for CRC Screening in Individuals 45-49 at Average Risk for CRC. — Completed
• BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity — Completed